Session » SLE – Treatment Poster I

Date: Saturday, November 7, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0857

Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory

9:00AM-11:00AM: Abstract Number: 0859

Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0848

Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial

9:00AM-11:00AM: Abstract Number: 0864

Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0865

Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study

9:00AM-11:00AM: Abstract Number: 0853

Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0849

Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 0852

How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis

9:00AM-11:00AM: Abstract Number: 0871

Hydroxychloroquine Dose Reduction and SLE Flares

9:00AM-11:00AM: Abstract Number: 0870

Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vascular Health in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0861

Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 0867

Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients

9:00AM-11:00AM: Abstract Number: 0851

Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature

9:00AM-11:00AM: Abstract Number: 0866

Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies

9:00AM-11:00AM: Abstract Number: 0847

Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity

9:00AM-11:00AM: Abstract Number: 0868

Impact of Proteinuria on the Clearance of Monoclonal Antibodies: Potential Clinical Implications

9:00AM-11:00AM: Abstract Number: 0858

Leflunomide: A Safe and Effective Alternative in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0854

Mortality and Adverse Events of Special Interest in Adult Patients with Systemic Lupus Erythematosus Receiving Intravenous Belimumab: A Post Hoc Descriptive Summary of Serious Psychiatric Events

9:00AM-11:00AM: Abstract Number: 0860

PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE

9:00AM-11:00AM: Abstract Number: 0863

Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States

9:00AM-11:00AM: Abstract Number: 0869

Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine

9:00AM-11:00AM: Abstract Number: 0856

Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels

9:00AM-11:00AM: Abstract Number: 0855

Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study

9:00AM-11:00AM: Abstract Number: 0872

Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia

9:00AM-11:00AM: Abstract Number: 0862

Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

9:00AM-11:00AM: Abstract Number: 0850

What Does It Mean to Be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].